AU2020326244B2 - Compound for combination treatment - Google Patents

Compound for combination treatment Download PDF

Info

Publication number
AU2020326244B2
AU2020326244B2 AU2020326244A AU2020326244A AU2020326244B2 AU 2020326244 B2 AU2020326244 B2 AU 2020326244B2 AU 2020326244 A AU2020326244 A AU 2020326244A AU 2020326244 A AU2020326244 A AU 2020326244A AU 2020326244 B2 AU2020326244 B2 AU 2020326244B2
Authority
AU
Australia
Prior art keywords
compound
dose
male
treatment
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020326244A
Other languages
English (en)
Other versions
AU2020326244A1 (en
Inventor
Simon COMERMA-STEFFENSEN
Dan Peters
Ulf Simonsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Initiator Pharma AS
Original Assignee
Initiator Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Initiator Pharma As filed Critical Initiator Pharma As
Publication of AU2020326244A1 publication Critical patent/AU2020326244A1/en
Application granted granted Critical
Publication of AU2020326244B2 publication Critical patent/AU2020326244B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU2020326244A 2019-08-06 2020-08-06 Compound for combination treatment Active AU2020326244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19190224.6 2019-08-06
EP19190224 2019-08-06
PCT/EP2020/072092 WO2021023805A1 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Publications (2)

Publication Number Publication Date
AU2020326244A1 AU2020326244A1 (en) 2022-03-17
AU2020326244B2 true AU2020326244B2 (en) 2025-06-05

Family

ID=67551141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020326244A Active AU2020326244B2 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Country Status (16)

Country Link
US (1) US20220288052A1 (https=)
EP (2) EP4009942B1 (https=)
JP (1) JP7605825B2 (https=)
KR (1) KR20220054593A (https=)
CN (1) CN114430679A (https=)
AU (1) AU2020326244B2 (https=)
BR (1) BR112022002169A2 (https=)
CA (1) CA3146837A1 (https=)
DK (1) DK4009942T3 (https=)
ES (1) ES2962648T3 (https=)
FI (1) FI4009942T3 (https=)
IL (1) IL290319B2 (https=)
MX (1) MX2022000356A (https=)
PL (1) PL4009942T3 (https=)
WO (1) WO2021023805A1 (https=)
ZA (1) ZA202200723B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4646204A1 (en) * 2023-01-03 2025-11-12 Initiator Pharma A/S Compound for treatment of erectile dysfunction
WO2025051846A1 (en) 2023-09-05 2025-03-13 Initiator Pharma A/S Compound for treatment of female sexual dysfunction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035034A1 (en) * 2004-09-30 2006-04-06 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008074798A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110207722A1 (en) * 2008-08-21 2011-08-25 Neurosearch A/S Treatment of anxiety disorders
US20140235669A1 (en) * 2010-01-29 2014-08-21 Aniona Aps Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012693A (es) * 2002-06-20 2005-03-23 Lundbeck & Co As H Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina.
RU2354377C2 (ru) * 2003-07-11 2009-05-10 Берингер Ингельхайм Ветмедика Гмбх Способ лечения или предупреждения заболеваний центральной нервной системы с использованием соединений, обладающих селективностью в отношении альфа-3-субъединицы бензодиазепинового рецептора

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035034A1 (en) * 2004-09-30 2006-04-06 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008074798A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110207722A1 (en) * 2008-08-21 2011-08-25 Neurosearch A/S Treatment of anxiety disorders
US20140235669A1 (en) * 2010-01-29 2014-08-21 Aniona Aps Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMONSEN U.ET AL: "Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 119, 1/10/2016, COPENHAGEN, DK, pages 63 - 74, XP055814318, ISSN: 1742-7835, DOI: 10.1111/bcpt.12653 *

Also Published As

Publication number Publication date
WO2021023805A1 (en) 2021-02-11
MX2022000356A (es) 2022-05-11
FI4009942T3 (fi) 2023-09-26
CN114430679A (zh) 2022-05-03
ES2962648T3 (es) 2024-03-20
BR112022002169A2 (pt) 2022-06-07
AU2020326244A1 (en) 2022-03-17
IL290319A (en) 2022-04-01
IL290319B2 (en) 2023-06-01
DK4009942T3 (da) 2023-10-23
EP4009942B1 (en) 2023-08-09
EP4009942A1 (en) 2022-06-15
CA3146837A1 (en) 2021-02-11
ZA202200723B (en) 2022-08-31
EP4241839A2 (en) 2023-09-13
JP7605825B2 (ja) 2024-12-24
US20220288052A1 (en) 2022-09-15
JP2022544463A (ja) 2022-10-19
PL4009942T3 (pl) 2024-04-08
EP4241839A3 (en) 2023-11-15
KR20220054593A (ko) 2022-05-03

Similar Documents

Publication Publication Date Title
RU2458691C2 (ru) Лечение посттравматического стрессового расстройства
CN101815438A (zh) 治疗依赖性的方法
EP4149452A1 (en) Combination treatment of liver disorders
CN117202907A (zh) 用于延迟人类男性的射精的方法
AU2020326244B2 (en) Compound for combination treatment
ES2260195T3 (es) Metodos de producir (r)-y (s)-didesmetil-sibutramina opticamente pura.
US20120010225A1 (en) Pharmaceutical composition
HK40099487A (en) Compound for combination treatment
HK40071713B (en) Compound for combination treatment
HK40071713A (en) Compound for combination treatment
KR20220098168A (ko) 간 장애의 치료
US20220387414A1 (en) Treating liver disorders
Wakelin A review of the properties of a new specific 5-HT reuptake inhibitor—fluvoxamine maleate
UA77506C2 (en) Use of citalopram for treatment of elevated blood pressure
Haddley Lu-AA-21004
HK1155063A (en) Treatment of post-traumatic stress disorder
CN101189043A (zh) 肾上腺素能α2B拮抗剂用于治疗血管舒缩症状的应用
Davis Comparison of Effect of Ondansetron Versus Palonosetron in the Prevention of Post Operative Nausea and Vomiting Following Laparoscopic Surgery In Female Patients: A Prospective Randomized Double Blind Study
NZ624056A (en) Compositions of buprenorphine and mu-opioid receptor antagonists
JP2010222347A (ja) Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2007004226A2 (en) Compositions and methods for treatment of male erectile dysfunction (ed)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)